Home/Pipeline/Allogeneic iPS Cell-derived NK Cell Therapy

Allogeneic iPS Cell-derived NK Cell Therapy

Solid Tumors

ResearchEarly R&D

Key Facts

Indication

Solid Tumors

Phase

Research

Status

Early R&D

Company

Takara Bio

About Takara Bio

Takara Bio is a global biotechnology company with a mission to contribute to the advancement of life sciences and the improvement of human health. It has established itself as a key provider of research reagents, instruments, and contract development and manufacturing (CDMO) services, particularly in the fields of cell and gene therapy. The company's strategic direction focuses on expanding its therapeutic pipeline, scaling its CDMO capabilities, and deepening its research tools portfolio to address growing market demands in precision medicine.

View full company profile

Therapeutic Areas

Oncology Rare Diseases Regenerative Medicine

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active